|
Use of cancer immunotherapies in the real-world in the setting of microsatellite instability. |
|
|
No Relationships to Disclose |
|
|
Employment - Flatiron Health |
|
|
Employment - Foundation Medicine |
|
|
No Relationships to Disclose |
|
|
Employment - Foundation Medicine |
|
|
No Relationships to Disclose |
|
|
Employment - Foundation Medicine |
|
|
Employment - Flatiron Health |
|
|
Employment - Foundation Medicine |
|
|
Employment - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine; Foundation Medicine |
Stock and Other Ownership Interests - Agios; Blueprint Medicines; Exelixis |
Patents, Royalties, Other Intellectual Property - patents via FOundation Medicine; Patents via Seres Health on microbiome stuff in non neoplastic disease (I) |
|
|
Employment - Flatiron Health |
Leadership - Athenahealth |
Stock and Other Ownership Interests - AthenaHealth; Flatiron Health; Orange Leaf Associates |
Consulting or Advisory Role - Bristol-Myers Squibb; Helsinn Therapeutics |
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); DARA BioSciences (Inst); Dendreon (Inst); GlaxoSmithKline (Inst); Helsinn Therapeutics (Inst); Pfizer (Inst) |
|
|
Employment - Flatiron Health |
Stock and Other Ownership Interests - Part of ETFs |
Other Relationship - Private Equities (I) |
|
|
Employment - Foundation Medicine |